Idorsia receives approval from Swissmedic for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral antihy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback